"ESMO 2025: MSD’s ADC leapfrogs to Phase III in colorectal cancer " was originally created and published by Clinical Trials ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with ...

Guardant Health is breaking barriers and hoping to get more people screened through the “Shield” test. In 2024, over 53,000 ...

An international team of researchers has uncovered a promising new avenue for treating colorectal cancer, the world's third ...

Colorectal cancer is the second leading cause of cancer-related deaths for males and females. Screening for colorectal cancer ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Guardant's liquid biopsy only requires a few vials of blood. Can it really prevent cancer?

Consumers have testing options beyond the once-a-decade colonoscopy. But some doctors question Cologuard's testing program.

Colorectal cancer is a cancer that starts in the colon (large intestine) or rectum. Often, it begins as abnormal growths ...

Among nearly 25 million privately insured adults, significant shifts in colorectal cancer (CRC) screening practices were identified after the onset of COVID-19. 1 Between 2017 and 2024, colonoscopy ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

Researchers from The University of Texas MD Anderson Cancer Center have discovered a previously unknown mechanism that ...